ClinicalTrials.gg
CompletedNCT02141698Updated May 19, 2014

Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects

A Phase 1 interventional study of TAK-438 and TAK-438 Placebo in Dose Finding Study, sponsored by Takeda. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-19.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The primary purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 following single or multiple doses of TAK-438 in healthy Western men, to investigate the effect of food on the pharmacokinetics of TAK-438, and to compare the TAK-438 pharmacokinetics of Western with Japanese men.

Read the detailed description

The drug being tested in this study is called TAK-438. TAK-438 is being tested to find a safe and well-tolerated dose. This study looked at the pharmacodynamic and pharmacokinetic properties (how the drug moves throughout the body) of the drug and safety (lab results and side effects) in people who took TAK-438.

This study was designed to consist of 4 sequential substudies: a single rising dose study (Cohorts 1 to 7), a food-effect study (Cohort 8), a multiple rising dose study (Cohorts 9 to 11), and a Japanese bridging study (Cohort 12). However, the protocol was halted during the food effect study (Cohort 8) following the discovery of previously unidentified metabolites and as a result, the multiple rising dose (Cohorts 9-11) and ethnicity (Cohort 12) studies were not carried out.

The study population for each of Cohorts 1 to 7 consisted of 9 subjects; with 6 subjects randomized to receive a single dose of TAK-438, and 3 subjects to receive placebo. Subjects in Cohorts 1 to 7 received a single dose of study drug after a 10-hour fast. The starting dose was 1 mg followed by administrations of 5, 10, 20, 15, 40, and 30 mg.

In Cohort 8 the plan was to assign 12 participants in a 2-sequence, 2-period crossover design. Six participants were to receive a single dose of TAK-438 on Day 1, in the fasted state, followed by a second single dose of TAK-438 on Day 15 in the alternative fed state. The other 6 participants were to receive the study drug like-wise but in the fed then fasted state.

To investigate the effect of multiple dosing, a further 3 cohorts (Cohorts 9-11), each comprising 12 participants were to be introduced to the protocol following completion of the single rising dose study. A final cohort, Cohort 12, consisting of 24 Western participants and 24 Japanese participants was to be used to assess the effect of TAK-438 and esomeprazole on the safety, tolerability, pharmacokinetics and pH of the stomach between these 2 ethnic groups.

This single-centre trial was conducted in the United Kingdom.

02

Conditions studied

  • Dose Finding Study

Keywords

  • Drug therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subjects aged 18 to 45, inclusive, who are in good health, as determined by medical history, physical examination, clinical laboratory evaluations and urine drug screen
  • The subject has the ability to tolerate the pH probe for 24 hours prior to Randomization (Day 1).

Exclusion criteria

Exclusion Criteria:

  • history of to any drug or food or any of TAK-438.
  • History of gastroesophageal reflux disease (GERD), symptomatic GERD, erosive esophagitis, duodenal ulcer,gastric ulcer, dyspepsia, Barrett's esophagus, or Zollinger-Ellison syndrome
  • The subject has a positive test result for Helicobacter pylori at the Initial Screening Visit.
  • Any clinically significant results from physical examinations or clinical laboratory results as deemed by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Cohort 1: TAK-438 1 mg

    TAK-438 1 mg, tablets, orally, once on Day 1.

    Drug: TAK-438

  • Experimental
    Cohort 2: TAK-438 5 mg

    TAK-438 5 mg, tablets, orally, once on Day 1.

    Drug: TAK-438

  • Experimental
    Cohort 3: TAK-438 10 mg

    TAK-438 10 mg, tablets, orally, once on Day 1.

    Drug: TAK-438

  • Experimental
    Cohort 4: TAK-438 20 mg

    TAK-438 20 mg, tablets, orally, once on Day 1.

    Drug: TAK-438

  • Experimental
    Cohort 5: TAK-438 15 mg

    TAK-438 15 mg, tablets, orally, once on Day 1.

    Drug: TAK-438

  • Experimental
    Cohort 6: TAK-438 40 mg

    TAK-438 40 mg, tablets, orally, once on Day 1.

    Drug: TAK-438

  • Experimental
    Cohort 7: TAK-438 30 mg

    TAK-438 30 mg, tablets, orally, once on Day 1.

    Drug: TAK-438

  • Experimental
    Cohort 8A: Food-effect

    TAK-438 20 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.

    Drug: TAK-438

  • Experimental
    Cohort 8B: Food-effect

    TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 1.

    Drug: TAK-438

  • Experimental
    Cohort 9: TAK-438 Multiple Dose 1

    TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.

    Drug: TAK-438

  • Experimental
    Cohort 10: TAK-438 Multiple Dose 2

    TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.

    Drug: TAK-438

  • Experimental
    Cohort 11: TAK-438 Multiple Dose 3

    TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.

    Drug: TAK-438

  • Experimental
    Cohort 12: Ethnic Bridging

    TAK-438 tablets, dose 1, orally, on Days 1-7 of Period 1, followed by a 4-week washout period followed by TAK-438 tablets, dose 2, orally, Days 1-7 of Period 2, followed by a 4-week washout period, followed by esomeprazole tablets, 40 mg, orally, on Days 1-7 of Period 3. TAK-438 doses to be determined from data collected in Cohorts 9-11.

    Drug: TAK-438 · Drug: Esomeprazole

  • Placebo comparator
    Cohorts 1-7: Placebo

    TAK-438 placebo-matching tablets, orally, once on Day 1

    Drug: TAK-438 Placebo

  • Placebo comparator
    Cohorts 9-11: Placebo

    TAK-438 placebo-matching tablets, orally, once on Day 1, where available, if required.

    Drug: TAK-438 Placebo

Interventions

  • TAK-438 tablets

  • DrugTAK-438 Placebo

    TAK-438 placebo-matching tablets

  • DrugEsomeprazole

    Esomeprazole tablets

06

What researchers measure

Primary outcomes

  1. AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438 and TAK-438 metabolites M-I and M-II

    (AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).

    Time frame: Day 1

  2. AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438 and TAK-438 metabolites M-I and M-II

    AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.

    Time frame: Day 1

  3. AUC(0-tau): Area Under the Plasma Concentration-time Curve from Time 0 to Time tau Over the Dosing Interval for TAK-438 and TAK-438 metabolites M-I and M-II

    AUC(0-tau) is a measure of the area under the plasma concentration-time curve from time 0 to time tau over a dosing interval, where tau is the length of the dosing interval.

    Time frame: Day 1

  4. Cmax: Maximum Observed Plasma Concentration for TAK-438 and TAK-438 metabolites M-I and M-II

    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration; obtained directly from the plasma concentration-time curve.

    Time frame: Day 1

  5. Cmin,ss: Minimum Observed Plasma Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I and M-II

    Time frame: Day 7

  6. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438 and TAK-438 metabolites M-I and M-II

    Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.

    Time frame: Day 1

  7. Terminal Elimination Rate Constant (λz) for TAK-438 and TAK-438 metabolites M-I and M-II

    Terminal elimination rate constant (λz) is the rate at which drugs are eliminated from the body.

    Time frame: Day 1

  8. Terminal Elimination Half-life (T1/2) Pharmacokinetic Parameter for TAK-438 and TAK-438 metabolites M-I and M-II

    Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

    Time frame: Day 1

  9. Apparent Clearance (CL/F) Pharmacokinetic Parameter for TAK-438 and TAK-438 metabolites M-I and M-II

    CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-24), expressed in L/hr.

    Time frame: Day 1

  10. Apparent Volume of Distribution (Vz/F) for TAK-438 and TAK-438 metabolites M-I and M-II

    Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by λz.

    Time frame: Day 1

  11. Total Amount of Drug Excreted in Urine for TAK-438 and TAK-438 metabolites M-I and M-II

    Time frame: Day 1

  12. Renal Clearance (CLr) for TAK-438 and TAK-438 metabolites M-I and M-II

    CLr is a measure of apparent clearance of the drug from the urine calculated as total amount excreted in the urine from time 0 to 24 hours postdose / plasma area under the curve from time 0 to 24 hours post-dose.

    Time frame: Day 1

  13. Fraction of TAK-438 Excreted in Urine (Fe)

    Fe is a measure of the fraction of drug excreted in urine and is calculated as Fe = (total amount excreted in the urine from time 0 to 24 hours post-dose / dose)×100.

    Time frame: Day 1

  14. Percentage of the Total Time the pH is Greater than pH 5

    Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 24-hour period at Baseline and over a 96-hour period following the administration of study drug.

    Time frame: Over a 24-hour period at Baseline and over a 96-hour period following the administration of study drug

  15. Percentage of Time the pH is Greater than pH 4 over a 24 Hour Period

    Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 24-hour period at Baseline and over a 24-hour period following the administration of study drug.

    Time frame: Over a 24-hour period at Baseline and over a 24-hour period following the administration of study drug

  16. Percentage of Time the pH is Greater than pH 5 over a 24 Hour Period.

    Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 24-hour period at Baseline and over a 24-hour period following the administration of study drug.

    Time frame: Over a 24-hour period at Baseline and over a 24-hour period following the administration of study drug

  17. Total Amount of Gastrin in Plasma

    Time frame: Baseline and Day 1

  18. Total Amount of Pepsinogen I/II in Plasma

    Time frame: Baseline and Day 1

  19. Physical Examination Findings

    A baseline physical examination (defined as the pretreatment assessment immediately prior to the start of study drug) will consist of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; (11) genitourinary system; and (12) other. All subsequent physical examinations should assess clinically significant changes from the baseline examination.

    Time frame: Baseline up to Day 30

  20. Number of Participants With Potentially Clinically Significant Vital Sign Findings

    Participants with at least one potentially clinically significant post-baseline vital sign finding. Vital signs will include body temperature (tympanic measurement), sitting blood pressure (BP) (after resting for 5 minutes), and pulse (beats per minute (bpm)).

    Time frame: Baseline up to Day 30

  21. Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings

    Time frame: Baseline to Day 30

  22. Number of Participants With Potentially Clinically Significant Telemetry Findings

    Time frame: Baseline up to Day 30

  23. Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings

    Laboratory tests for hematology, serum chemistry and urinalysis will be performed.

    Time frame: Baseline up to Day 30

  24. Number of Participants With Treatment-Emergent Adverse Events (AEs)

    Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug.

    Time frame: Baseline up to Day 30

  25. Percentage of Time the pH is Greater than pH 4 from 8PM to 8AM.

    Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 12-hour period at Baseline and over a 12-hour period following the administration of study drug.

    Time frame: Over a 12-hour period at Baseline and over a 12-hour period between 8PM and 8AM following the administration of study drug

  26. • Percentage of Time the pH is Greater than pH 5 from 8 PM to 8 AM

    Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 12-hour period at Baseline and over a 12-hour period following the administration of study drug.

    Time frame: Over a 12-hour period at Baseline and over a 12-hour period between 8pm and 8 am following the administration of study drug

  27. • Percentage of the Total Time the pH is Greater than pH 4

    Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 24-hour period at Baseline and over a 96-hour period following the administration of study drug.

    Time frame: Over a 24-hour period at Baseline and over a 96-hour period following the administration of study drug

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2014
First posted
May 19, 2014
Start
Oct 2007
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Last update
May 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02141698
Lead sponsor
Takeda
Collaborators
Richmond Pharmacology Limited
Responsible party
Sponsor
First posted
May 19, 2014
Start date
Oct 2007
Primary completion
Feb 2008
Completion
Feb 2008
Last update
May 19, 2014

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion